TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20494998

Group type: EXPERIMENTAL
Intervention: Higher body mass index (BMI) at ages 20 and 50 years and at baseline
Number of subjects: 142982

Group type: COMPARATOR
Intervention: Ever smoking
Number of subjects: 142982

Group type: COMPARATOR
Intervention: Alcohol consumption (drinks/week)
Number of subjects: 142982
Study: 20496155

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Number of subjects: 10
Study: 20497573

Group type: EXPERIMENTAL
Intervention: Spinal manipulation
Number of subjects: 80

Group type: COMPARATOR
Intervention: Light massage control
Number of subjects: 80
Study: 20497785

Group type: EXPERIMENTAL
Intervention: Nutrition and physical activity intervention (IMPACT study)
Number of subjects: 717
Study: 20501469

Group type: EXPERIMENTAL
Intervention: Severe oligozoospermia (SO)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Recurrent spontaneous abortion (RSA)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Healthy sperm donors (SD)
Number of subjects: 90
Study: 20501583

Group type: EXPERIMENTAL
Intervention: Single lens distance glasses
Number of subjects: 606

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 606
Study: 20501690

Group type: EXPERIMENTAL
Intervention: Gastric bypass surgery (GBP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Diet-induced equivalent weight loss
Number of subjects: 20
Study: 20502869

Group type: EXPERIMENTAL
Intervention: Noninvasive regional transcranial oxygen saturation (rSO(2))
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Invasive brain tissue oxygen pressure (PbrO(2))
Number of subjects: 22
Study: 20504975

Group type: EXPERIMENTAL
Intervention: Males in late puberty (mean +/- SE: 1955 +/- 70 kcal)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Females in late puberty (1388 +/- 68 kcal)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Overall energy intake by males
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Energy intake adjusted for fat-free mass, fat mass, height, overweight status, race, and meal instruction
Number of subjects: 204
Study: 20505894

Group type: EXPERIMENTAL
Intervention: pT3 patients with minimal extrathyroidal extension
Number of subjects: 347

Group type: COMPARATOR
Intervention: pT4a patients with extensive extrathyroidal growth
Number of subjects: 347
Study: 20507207

Group type: EXPERIMENTAL
Intervention: Etravirine (ETR)
Number of subjects: 673

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 673
Study: 20507945

Group type: EXPERIMENTAL
Intervention: CTD-APAH
Number of subjects: 641

Group type: COMPARATOR
Intervention: SSc-APAH
Number of subjects: 641
Study: 20508186

Group type: EXPERIMENTAL
Intervention: Copeptin levels measured on admission
Number of subjects: 362
Study: 20508619

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 400 mg/m(2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide 500 mg/m(2)
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VDCR (Bortezomib, Dexamethasone, Cyclophosphamide, Lenalidomide)
Number of subjects: 25
Study: 20510210

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose
Number of subjects: 760
Study: 20510214

Group type: EXPERIMENTAL
Intervention: Myocardial salvage index (MSI) > median
Number of subjects: 208

Group type: COMPARATOR
Intervention: Myocardial salvage index (MSI) < median
Number of subjects: 208
Study: 20511445

Group type: COMPARATOR
Intervention: Lp(a) quintiles 2-5 vs quintile 1
Number of subjects: 26746

Group type: COMPARATOR
Intervention: Nonfasting women Lp(a) quintiles 2-5 vs quintile 1
Number of subjects: 26746

Group type: COMPARATOR
Intervention: Lp(a) <10 mg/L and Hb A(1c) <5%
Number of subjects: 26746

Group type: COMPARATOR
Intervention: Nonfasting Danish men and women Lp(a) quintiles 2-5 vs quintile 1
Number of subjects: 26746
Study: 20511662

Group type: EXPERIMENTAL
Intervention: Intermediate risk group (with at least one of: unmutated IGHV genes and/or IGHV3-21 usage, 11q deletion, β-2 microglobulin greater than 4 mg/L)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Good risk group (with none of the above and mutated IGHV genes)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Poor risk group (with known TP53 loss of greater than 10%)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Intermediate-low risk (one risk factor)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Intermediate-high risk (2 or 3 risk factors)
Number of subjects: 250
Study: 20516271

Group type: EXPERIMENTAL
Intervention: 10 mg/kg once-daily lamivudine (3TC) for children below 17 kg
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: 8 mg/kg once-daily lamivudine (3TC) for children over 17 kg
Number of subjects: 49

Group type: COMPARATOR
Intervention: Didanosine-lamivudine-efavirenz treatment
Number of subjects: 49
Study: 20517912

Group type: EXPERIMENTAL
Intervention: LiDCO Plus monitor (calibrated)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: FloTrac-Vigileo monitor (uncalibrated)
Number of subjects: 20
Study: 20518811

Group type: EXPERIMENTAL
Intervention: Pramlintide added to mealtime insulin
Number of subjects: 1297
Study: 20519658

Group type: EXPERIMENTAL
Intervention: Antibody positive subjects (GAD-65 and IA-2 autoantibodies)
Number of subjects: 1206

Group type: COMPARATOR
Intervention: Antibody negative subjects
Number of subjects: 1206
Study: 20519661

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Balloon angioplasty (BA)
Number of subjects: 1846

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 1846
Study: 20521331

Group type: EXPERIMENTAL
Intervention: Michigan Hand Questionnaire (MHQ)
Number of subjects: 128
Study: 20522711

Group type: EXPERIMENTAL
Intervention: Fibril-reactive, amyloidolytic murine IgG1 mAb 11-1F4 labeled with I-124, infused with less than 1 mg (∼ 74 MBq) of GMP-grade antibody.
Number of subjects: 18
Study: 20523092

Group type: EXPERIMENTAL
Intervention: Oxaliplatin 70 mg/m(2) on days 1 and 15, irinotecan 100 mg/m(2) on days 8 and 22, capecitabine (dose levels 1-5, between 800 and 1,600 mg/m(2)) on days 1-29 every 5 weeks.
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Capecitabine at the recommended dose of 1,400 mg/m(2) daily.
Number of subjects: 23
Study: 20524979

Group type: COMPARATOR
Intervention: Normal individuals (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Gray platelet syndrome (GPS) patients
Number of subjects: 0
Study: 20525721

Group type: EXPERIMENTAL
Intervention: Trimodality therapy (induction chemotherapy with cisplatin 75 mg·m⁻² and pemetrexed 500 mg·m⁻², followed by extrapleural pneumonectomy and post-operative radiotherapy at 54 Gy, 30 fractions)
Number of subjects: 58
Study: 20529243

Group type: EXPERIMENTAL
Intervention: Ezetimibe (10 mg/day)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Simvastatin (20 mg/day)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Combined therapy (simvastatin and ezetimibe)
Number of subjects: 50
Study: 20529376

Group type: EXPERIMENTAL
Intervention: Adapted cardiac rehabilitation (CR) intervention for 6 months
Number of subjects: 43
Study: 20530034

Group type: EXPERIMENTAL
Intervention: Riociguat 1.0-2.5 mg t.i.d. titrated according to systemic systolic blood pressure (SBP)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Riociguat
Number of subjects: 75
Study: 20530048

Group type: EXPERIMENTAL
Intervention: Doxorubicin (60 mg·m⁻²) plus valproic acid
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group not applicable
Number of subjects: 45
Study: 20530284

Group type: EXPERIMENTAL
Intervention: Radioimmunotherapy (RIT) using yttrium-90-ibritumomab-tiuxetan (15 MBq [0.4 mCi]/kg) with reduced-intensity conditioning (RIC) using fludarabine (90 mg/m(2)) and 2 Gy total body irradiation followed by allogeneic hematopoietic cell transplantation (HCT)
Number of subjects: 40
Study: 20534736

Group type: EXPERIMENTAL
Intervention: Volumetric measurement using semiautomated algorithm
Number of subjects: 48

Group type: COMPARATOR
Intervention: Unidimensional measurement
Number of subjects: 48
Study: 20534744

Group type: EXPERIMENTAL
Intervention: Negative mood condition
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Maternal use of food for emotion regulation
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Maternal use of restriction, pressure to eat, and use of foods as a reward
Number of subjects: 25
Study: 20535444

Group type: EXPERIMENTAL
Intervention: Glycaemic control intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (type 2 diabetes)
Number of subjects: 0
Study: 20535449

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) in women with detrusor overactivity (DO)
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) for urgency urinary incontinence
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) for 'pure DO'
Number of subjects: 247

Group type: EXPERIMENTAL
Intervention: Ultrasound measurement of bladder wall thickness (BWT) for 'all DO'
Number of subjects: 247
Study: 20537128

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 2054
Study: 20537130

Group type: EXPERIMENTAL
Intervention: Olanzapine long-acting injection (LAI)
Number of subjects: 30
Study: 20537292

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control subjects (CRS without immune dysfunction)
Number of subjects: 22
Study: 20538956

Group type: EXPERIMENTAL
Intervention: Mitochondrial biogenesis and antioxidant defense responses in critically ill patients.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Mitochondrial morphology and protein content in critically ill patients.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: mRNA content of peroxisome proliferator-activated receptor γ coactivator 1-α in critically ill patients.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Manganese superoxide dismutase in critically ill patients.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Microarray analysis and phosphorylated (energy) metabolites in critically ill patients.
Number of subjects: 16
Study: 20538985

Group type: EXPERIMENTAL
Intervention: Substantial lens bacterial bioburden
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Smoking
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Corneal staining (mild or greater)
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Cumulative probability of remaining CIE free
Number of subjects: 205
Study: 20539305

Group type: EXPERIMENTAL
Intervention: HIV-infected participants
Number of subjects: 425

Group type: EXPERIMENTAL
Intervention: Stavudine use
Number of subjects: 425

Group type: COMPARATOR
Intervention: Controls
Number of subjects: 425
Study: 20540778

Group type: EXPERIMENTAL
Intervention: RV5
Number of subjects: 57000
Study: 20542323

Group type: EXPERIMENTAL
Intervention: Mepolizumab
Number of subjects: 0
Study: 20542776

Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (asymptomatic patients)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (symptomatic patients)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (patients <80 years)
Number of subjects: 454

Group type: EXPERIMENTAL
Intervention: NexStent and Filterwire EX/EZ devices (patients >=80 years)
Number of subjects: 454
Study: 20542797

Group type: EXPERIMENTAL
Intervention: TAXUS Petal paclitaxel-eluting bifurcation stent
Number of subjects: 28
Study: 20545713

Group type: EXPERIMENTAL
Intervention: Fluid administration (200 mL of hydroxyethyl starch, HES 130/0.4)
Number of subjects: 20
Study: 20545869

Group type: EXPERIMENTAL
Intervention: Automated atrial threshold measurements
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Automated RV threshold measurements
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Threshold tracking feature On
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Reduced ventricular pacing
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Reduced atrial pacing
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: High impedance leads (> or =1,000 ohms)
Number of subjects: 691

Group type: EXPERIMENTAL
Intervention: Increase in device size (1-cc)
Number of subjects: 691
Study: 20546561

Group type: EXPERIMENTAL
Intervention: Fasting AEA levels
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Non-fasting AEA levels after lunch with beer
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Non-fasting AEA levels after lunch with alcohol-free beer
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: AEA levels
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: OEA levels
Number of subjects: 41
Study: 20547978

Group type: EXPERIMENTAL
Intervention: Overfeeding by +1,250 kcal/day (45% fat) for 28 days
Number of subjects: 36
Study: 20549047

Group type: EXPERIMENTAL
Intervention: Photorefractive keratectomy (PRK) with mitomycin-C (MMC)
Number of subjects: 60
Study: 20549827

Group type: EXPERIMENTAL
Intervention: Aromatase inhibitors (letrozole or exemestane)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Baseline wrist ultrasound
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Patient-reported symptoms
Number of subjects: 30
Study: 20550679

Group type: EXPERIMENTAL
Intervention: 166Ho-PLLA-MS radioembolization (166Ho-RE)
Number of subjects: 15
Study: 20550691

Group type: EXPERIMENTAL
Intervention: 10s epochs
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: 60s epochs
Number of subjects: 102
Study: 20550698

Group type: EXPERIMENTAL
Intervention: Hyperbaric oxygen therapy (HBO)
Number of subjects: 49

Group type: COMPARATOR
Intervention: Hydroxycobalamin (given to some patients before HBO)
Number of subjects: 49
Study: 20550701

Group type: EXPERIMENTAL
Intervention: Sputum neutrophil measurements
Number of subjects: 488
Study: 20550973

Group type: EXPERIMENTAL
Intervention: Thrombus aspiration
Number of subjects: 0
Study: 20551376

Group type: EXPERIMENTAL
Intervention: BACOPP regimen (bleomycin, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone) administered in 6 to 8 cycles; 75% of treatment courses were administered according to protocol
Number of subjects: 65
Study: 20551454

Group type: EXPERIMENTAL
Intervention: Reflux Disease Questionnaire (RDQ)
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Family practitioners
Number of subjects: 308

Group type: EXPERIMENTAL
Intervention: Gastroenterologists
Number of subjects: 308

Group type: COMPARATOR
Intervention: Esomeprazole (40 mg for 2 weeks)
Number of subjects: 308
Study: 20553600

Group type: EXPERIMENTAL
Intervention: Adalimumab 40 mg every other week
Number of subjects: 326
Study: 20554713

Group type: EXPERIMENTAL
Intervention: tesamorelin 2 mg sc daily
Number of subjects: 806

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 806
Study: 20555351

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB radiation therapy (NB-UVB) for 6 weeks
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Narrow-band UVB radiation therapy (NB-UVB)
Number of subjects: 14
Study: 20557308

Group type: EXPERIMENTAL
Intervention: GeneSearch Breast Lymph Node (BLN) Assay
Number of subjects: 97
Study: 20558556

Group type: EXPERIMENTAL
Intervention: REVEAL patients
Number of subjects: 2967
Study: 20559034

Group type: EXPERIMENTAL
Intervention: Single vaccination with a split virion, inactivated, adjuvanted pandemic H1N1 influenza vaccine (A/California/7/2009)
Number of subjects: 160
Study: 20560801

Group type: EXPERIMENTAL
Intervention: Storage time at -20°C
Number of subjects: 534
Study: 20560883

Group type: EXPERIMENTAL
Intervention: Rectal luminal lactate concentration
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Arterial blood lactate concentration
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Rectal-arterial difference of lactate concentration
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Blood pressure, noradrenaline dose, central venous oxygen saturation
Number of subjects: 130
Study: 20561184

Group type: EXPERIMENTAL
Intervention: Isolated DVT
Number of subjects: 646

Group type: COMPARATOR
Intervention: Isolated PE
Number of subjects: 646

Group type: EXPERIMENTAL
Intervention: DVT and PE
Number of subjects: 646

Group type: COMPARATOR
Intervention: Isolated DVT vs. Isolated PE
Number of subjects: 646
Study: 20562120

Group type: EXPERIMENTAL
Intervention: Obstructive sleep apnoea (OSA) patients with left ventricular diastolic dysfunction
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mean nocturnal oxygen saturation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Age ≥ 58 yrs
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Mean nocturnal oxygen saturation < 92%
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Clinic systolic blood pressure and mean nocturnal oxygen saturation
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Left ventricular hypertrophy
Number of subjects: 150
Study: 20562130

Group type: EXPERIMENTAL
Intervention: Lung injury prediction score (derived from logistic regression analysis)
Number of subjects: 872

Group type: EXPERIMENTAL
Intervention: Lung injury prediction score (validated in an independent cohort)
Number of subjects: 872
Study: 20562526

Group type: EXPERIMENTAL
Intervention: Co-culture of immortalized human fibroblasts with MCF7 breast cancer cells
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: siRNA-mediated Cav-1 downregulation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Chloroquine or other autophagy/lysosome inhibitors
Number of subjects: 0
Study: 20564111

Group type: EXPERIMENTAL
Intervention: Tumor diameter >5 cm
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Clinically positive nodes (N+)
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Combination of tumor diameter >5 cm and N+
Number of subjects: 644

Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 644
Study: 20564750

Group type: EXPERIMENTAL
Intervention: Multilevel surgical treatment (uvulopalatopharyngoplasty, tonsillectomy, genioglossus advancement, with or without hyoid suspension)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Multilevel surgical treatment
Number of subjects: 30
Study: 20565828

Group type: EXPERIMENTAL
Intervention: Colon Capsule Endoscopy (CCE)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Conventional Colonoscopy (CSPY)
Number of subjects: 59
Study: 20566896

Group type: EXPERIMENTAL
Intervention: Deferasirox
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Deferasirox (chelation-naive)
Number of subjects: 116

Group type: EXPERIMENTAL
Intervention: Deferasirox (previously chelated)
Number of subjects: 116
Study: 20569704

Group type: EXPERIMENTAL
Intervention: Frequent optimization of AV and VV delays every 3 months using a new device-based algorithm.
Number of subjects: 1580

Group type: COMPARATOR
Intervention: Standard of care arm (empiric device programming or non-device-based method of CRT optimization).
Number of subjects: 1580
Study: 20569720

Group type: EXPERIMENTAL
Intervention: Carotid ultrasound with measurement of intima-media thickness (IMT)
Number of subjects: 150
Study: 20570701

Group type: COMPARATOR
Intervention: Multi-item lunch (AN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Macaroni and cheese lunch (AN)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Yogurt snack (AN)
Number of subjects: 0
Study: 20571134

Group type: COMPARATOR
Intervention: Control arm (no screening)
Number of subjects: 38350

Group type: EXPERIMENTAL
Intervention: Screened arm (with PSA and DRE screening)
Number of subjects: 38350
Study: 20573151

Group type: EXPERIMENTAL
Intervention: Acupuncture (twice on the same day at acupuncture point GV20 and bilaterally at points BL67, LI4 and SP6)
Number of subjects: 125

Group type: COMPARATOR
Intervention: Sham acupuncture (at the same points)
Number of subjects: 125
Study: 20573639

Group type: EXPERIMENTAL
Intervention: Be Fit, Be Well
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: POWER Hopkins
Number of subjects: 1100

Group type: EXPERIMENTAL
Intervention: POWER-UP
Number of subjects: 1100
Study: 20573788

Group type: EXPERIMENTAL
Intervention: VAT (visceral adipose tissue) categorized into tertiles
Number of subjects: 99

Group type: COMPARATOR
Intervention: African American group
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: VAT
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: HFF
Number of subjects: 99
Study: 20573794

Group type: EXPERIMENTAL
Intervention: Citrus consumption (proline betaine as a biomarker)
Number of subjects: 1998

Group type: EXPERIMENTAL
Intervention: Citrus consumers
Number of subjects: 1998

Group type: COMPARATOR
Intervention: Noncitrus consumers
Number of subjects: 1998
Study: 20576011

Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IVIG administration
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Serial testing before and after IVIG
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: IVIG products
Number of subjects: 24
Study: 20576398

Group type: EXPERIMENTAL
Intervention: Carotid artery stenting (CAS)
Number of subjects: 5297
Study: 20579539

Group type: EXPERIMENTAL
Intervention: Coronary flow reserve (CFR) after intracoronary adenosine
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: CFR <2.32
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: CFR <2.32 among women without obstructive CAD
Number of subjects: 189

Group type: EXPERIMENTAL
Intervention: CFR
Number of subjects: 189
Study: 20579630

Group type: EXPERIMENTAL
Intervention: 20% topical autologous serum
Number of subjects: 165

Group type: COMPARATOR
Intervention: No use of topical autologous serum
Number of subjects: 165
Study: 20581689

Group type: EXPERIMENTAL
Intervention: Fibrinogen levels in the highest tertile (>406 mg/dL)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: High CRP (>3 mg/L)
Number of subjects: 922

Group type: EXPERIMENTAL
Intervention: Fibrinogen (as a linear variable) per 100 mg/dL increase
Number of subjects: 922
Study: 20582937

Group type: EXPERIMENTAL
Intervention: Bortezomib 1.3 mg/m(2) with VXLD chemotherapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bortezomib 1 mg/m(2) with VXLD chemotherapy
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Bortezomib with VXLD chemotherapy
Number of subjects: 10
Study: 20584275

Group type: EXPERIMENTAL
Intervention: Behavior therapy (N = 12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Minimal attention control (N = 12)
Number of subjects: 24
Study: 20584291

Group type: EXPERIMENTAL
Intervention: HES 200/0.5 (10%)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Crystalloids only
Number of subjects: 30